Can a common MS drug slow blindness in AMD?
NCT ID NCT04292080
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether an oral drug called dimethyl fumarate (Tecfidera) can safely slow the growth of geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 90 adults aged 55–85 with geographic atrophy will take the drug for 12 months. Researchers will measure changes in the size of the damaged area in the eye and track any side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION (AMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre intercommunal de Créteil
RECRUITINGCréteil, Val De Marne, 94000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can At-Home eye scans personalize wet AMD treatment?
- AI eye doctor: could a computer spot Blindness-Causing diseases faster than humans?
- Gene therapy injection aims to halt blinding eye disease
- Scientists track Long-Term safety of experimental AMD therapy
- AMD Patients' knowledge gaps revealed in new study
- Cheaper eye drug could save millions in AMD treatment costs